4.6 Article

Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody

期刊

CANCER IMMUNOLOGY RESEARCH
卷 1, 期 3, 页码 163-167

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-13-0049

关键词

-

资金

  1. NIH [5R01-CA135272-04, 5P50-NS020023-29, 3R25-NS065731-03S1, 1F30CA177152-01]
  2. Pediatric Brain Tumor Foundation
  3. Ben and Catherine Ivy Foundation
  4. Duke Cancer Institute
  5. Cancer Research Institute
  6. Miami Brain Tumor Coalition

向作者/读者索取更多资源

A major mechanism by which human regulatory T cells (T-reg) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T-regs also possess the capacity to kill tumor cells using similar mechanisms. Bispecific antibodies (bscAb) have emerged as a promising class of therapeutics that activate T cells against tumor antigens without the need for classical MHC-restricted T-cell receptor (TCR) recognition. Here, we show that a bscAb targeting the tumor-specific mutation of the EGF receptor, EGFRvIII, redirects human CD4(+)CD25(+)FoxP3(+) T-regs to kill glioblastoma cells. This activity was significantly abrogated by inhibitors of the granzyme-perforin pathway. Notably, analyses of human primary glioblastoma also displayed diffused infiltration of granzyme-expressing FoxP3(+) T cells. Together, these data suggest that despite their known suppressive functions, tumor-infiltrating T-regs possess potent cytotoxic mechanisms that can be co-opted for efficient tumor cell lysis. (C) 2013 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据